It's time for the World to see the lies. All forms of collectivism are the same in their roots. Hitler was a socialist and what we would call today a leftist.
This is 8 years of data.
When all 4 oscillators turn downwards into overbought territory after a strong upward trend like the one of the last few months, a corrective move always follows.
Do with this information what you want.
Back at home from Flight 13, the lucky one. It took 1 hour to get there and 3 months to get back. Incredible.
Bearish flag confirmed.
Every single indicator I look at is showing a downturn in the crypto market. We have been on a bullish trend since July 1, more than 3 months with vertical movements. A correction is well overdue.
This dip is for buying, not for shorting.
"He better damn well stop!"
President Donald Trump delivers a blunt warning to Ukrainian President Volodymyr Zelenskyy over strikes on Russian oil refineries, saying he specifically told him not to target facilities that supply diesel fuel to the global market.
Trump argues the attacks risk creating worldwide fuel shortages that could hurt American farmers and ranchers.
Stay up to date with the latest headlines and breaking news — download the FOX News app: foxnews.onelink.me/xLDS/z2jy…
Why my timeline is suddenly flooded with posts translated from arabic with content I never liked or am interested into? Anyone else experiencing this degradation of the algo?
Results from the first phase of the first human clinical trial on epigenetic rejuvenation have just been published. It was tested on patients with glaucoma, a disease that causes vision loss.
TL;DR
It went well. There were no adverse effects at a low dose, and two out of three patients are already experiencing a slight recovery of vision. The study is moving to Phase 2, where the dosage used in Phase 1 will be tripled.
It is worth noting that if this clinical trial succeeds, it could pave the way for curing a wide range of currently incurable age-related diseases.
Today we announced interim data from our first-in-human, Phase 1 clinical trial evaluating our lead program in optic neuropathies, showing it was well-tolerated by 3 participants with glaucoma.
Read more about our safety & visual field observations here:bit.ly/4ASWq0p



























